The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Clovis Oncology, Inc. | Common Stock | 189464100 | 14,259,560 | 407,416 | SH | OTR | 0 | 407,416 | 0 | ||
Five Prime Therapeutics, Inc. | Common Stock | 33830X104 | 45,324,308 | 1,092,152 | SH | OTR | 0 | 1,092,152 | 0 | ||
CymaBay Therapeutics, Inc. | Common Stock | 23257D103 | 1,772,135 | 1,048,601 | SH | OTR | 0 | 1,048,601 | 0 | ||
Achaogen, Inc. | Common Stock | 004449104 | 7,353,812 | 1,281,152 | SH | OTR | 0 | 1,281,152 | 0 | ||
Biotie Therapies Corp. | ADS | 09074D103 | 3,855,443 | 268,672 | SH | OTR | 0 | 268,672 | 0 | ||
Ocular Therapeutix, Inc. | Common Stock | 67576A100 | 20,758,148 | 2,215,384 | SH | OTR | 0 | 1,281,152 | 0 | ||
Glaukos Corporation | Common Stock | 377322102 | 77,581,337 | 32,016,637 | SH | OTR | 0 | 268,672 | 0 |